Literature DB >> 1134885

Special devices as aids in the management of child self-mutilation in the Lesch-Nyhan syndrome.

R M Letts, D A Hobson.   

Abstract

The Lesch-Nyhan syndrome is a rare inborn error of purine metabolism associated with hyperuricacidemia, mental retardation, and an insatiable urge for self-mutilation, especially of the extremities. Insensitivity to pain and severe muscle spasms create very difficult management problems, especially for children being cared for at home. Fortunately this syndrome is rare (1 per 380,000 live births). Four known patients are under treatment in Manitoba, of which two brothers are the subject of this study. In general, the medical management of these patients has been unsuccessful, especially in controlling self-mutilation. It therefore was decided to manage these children by the use of mechanical aids. Through the utilization of custom-designed seating devices control of the self-mutilation has been obtained, reducing the burden of family care. It is now possible for the children to attend regular school on a half-day basis. They are also able to engage in community activities without the fear that a mishap will occur when not under the vigilance of the immediate family.

Entities:  

Mesh:

Year:  1975        PMID: 1134885

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  3 in total

1.  Cognitive abilities of patients with Lesch-Nyhan disease.

Authors:  L T Anderson; M Ernst; S V Davis
Journal:  J Autism Dev Disord       Date:  1992-06

2.  Flexible arm splints in the control of a Lesch-Nyhan victim's finger biting and a profoundly retarded client's finger sucking.

Authors:  T S Ball; P C Datta; M Rios; C Constantine
Journal:  J Autism Dev Disord       Date:  1985-06

Review 3.  Left to themselves: Time to target chronic pain in childhood rare diseases.

Authors:  Christine B Sieberg; Alyssa Lebel; Erin Silliman; Scott Holmes; David Borsook; Igor Elman
Journal:  Neurosci Biobehav Rev       Date:  2021-03-24       Impact factor: 8.989

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.